Literature DB >> 7081323

Oral contraceptives and prolactinomas: a case-control study.

R Maheux, M Jenicek, R Cleroux, H Beauregard, X De Muylder, N M Gratton, J Van Campenhout.   

Abstract

The increase in the number of newly diagnosed cases of prolactinomas seems to coincide with the use of oral contraceptives during the past two decades. The following retrospective case-control study was undertaken in an attempt to disprove a null hypothesis of relationship between oral contraceptive use and prolactinomas. Each of 70 patients operated upon for removal of a prolactinoma was closely matched for age, gravidity, and year of final diagnosis with one patient in each of three control groups. The control groups selected were constituted, respectively, of patients with secondary amenorrhea and normal prolactin levels, patients with normal ovulatory cycles consulting for infertility, and subjects without medical or gynecologic problems. No statistically significative differences were found in the exposure rates to oral contraceptives among four groups. This study thus failed to reveal a significant association between prolactinomas and oral contraceptives but, given the sample size, a relative risk lower than 3.32 cannot be demonstrated or disproved.

Entities:  

Keywords:  Americas; Biology; Body Weight; Canada; Cancer; Contraception; Contraception Continuation; Contraceptive Methods--side effects; Control Groups; Data Analysis; Demographic Factors; Developed Countries; Diseases; Endocrine System; Ethnic Groups; Family Planning; Hormones; Marital Status; Neoplasms; North America; Northern America; Oral Contraceptives--side effects; Physiology; Pituitary Gland--complications; Pituitary Hormones; Population; Population Characteristics; Prolactin--analysis; Religion; Research Methodology; Retrospective Studies; Studies

Mesh:

Substances:

Year:  1982        PMID: 7081323     DOI: 10.1016/0002-9378(82)90641-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  [Not Available].

Authors:  R Maheux
Journal:  Can Fam Physician       Date:  1983-04       Impact factor: 3.275

2.  Oral Contraceptive and Menopausal Hormone Therapy Use and Risk of Pituitary Adenoma: Cohort and Case-Control Analyses.

Authors:  David J Cote; John L Kilgallon; Noah L A Nawabi; Hassan Y Dawood; Timothy R Smith; Ursula B Kaiser; Edward R Laws; JoAnn E Manson; Meir J Stampfer
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

3.  Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia.

Authors:  P Touraine; C Deneux; G Plu-Bureau; P Mauvais-Jarvis; F Kuttenn
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

4.  Body Habitus Across the Lifespan and Risk of Pituitary Adenoma.

Authors:  David J Cote; Timothy R Smith; Ursula B Kaiser; Edward R Laws; Meir J Stampfer
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

5.  Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.

Authors:  Renato Cozzi; Maria Rosaria Ambrosio; Roberto Attanasio; Claudia Battista; Alessandro Bozzao; Marco Caputo; Enrica Ciccarelli; Laura De Marinis; Ernesto De Menis; Marco Faustini Fustini; Franco Grimaldi; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Marco Losa; Pietro Maffei; Davide Milani; Maurizio Poggi; Michele Zini; Laurence Katznelson; Anton Luger; Catalina Poiana
Journal:  Eur J Endocrinol       Date:  2022-02-03       Impact factor: 6.664

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.